Sonoma Pharmaceuticals, Inc. (SNOA)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA). The investigation concerns whether Sonoma and certain of its officers and/or directors have violated federal securities laws.


On November 17, 2020, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that its “unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020 should no longer be relied upon.” Sonoma explained that its financial statements for this time period “contained material errors” and that “the Company will need to restate them.” Following this news, Sonoma stock dropped $1.10 per share, or over 14%, to close at $6.63 on the next trading day.


If you are aware of any facts relating to this investigation, or purchased Sonoma shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.